Karim Fizazi, MD, PhD
Enriched profileGeneral Director (Directeur Général) of Centre Oscar Lambret; Professor of Oncology, Université Paris-Saclay; Medical Oncologist · Centre Oscar Lambret
Karim Fizazi is General Director (Directeur Général) of Centre Oscar Lambret; Professor of Oncology, Université Paris-Saclay; Medical Oncologist at Centre Oscar Lambret. OpenAlex indexes 1,575 publications with 84,733 citations (h-index 125); ClinicalTrials.gov lists 23 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Karim Fizazi is General Director (Directeur Général) of Centre Oscar Lambret. The public record shows 1,575 publications with 84,733 citations (h-index 125), centered on Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment. It also documents an investigator role on 23 registered clinical trials.
- Most recent indexed publication: 2026 · American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
- Top research focus: Prostate Cancer Treatment and Research
- 23 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 535.
Clinical & industry
trials, payments and federal fundingNot shown. No U.S. clinical registration on file.
Federally funded research awards.
Public positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Centre Oscar Lambret, 3 rue Frédéric Combemale, 59000 Lille, France
Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 23 registered studies on ClinicalTrials.gov. The most recent:
- Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Review2026 - Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
Journal of clinical oncology
Guideline2026 - Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Future oncology (London, England)
Article2025 - Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy4,583 citations2012
- 02Abiraterone and Increased Survival in Metastatic Prostate Cancer4,400 citations2011
- 03Enzalutamide in Metastatic Prostate Cancer before Chemotherapy3,036 citations2014
- 04Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy2,796 citations2012
- 05Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer2,618 citations2021
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
fr.linkedin.com/in/karim-fizazi-93572a3b9
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fr.linkedin.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/CentreOscarLambret/posts/1476379280581282
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
centreoscarlambret.fr/dr-karim-fizazi
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗ - X / Twitter
N/A
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →source ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - ResearchGate
ResearchGate scientific-contributions stub, "Karim Fizazi's research works | University of Paris-Saclay and other places", 919 works, 68,754 citations (auto-generated/unclaimed aggregation page)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗ - Source
Institutional X/Twitter mention only (@GustaveRoussy posting about ASCO GU19 ARAMIS trial); no owned X/Twitter account found for the individual after exhausted search variants
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →source ↗ - Facebook
Facebook, Centre Oscar Lambret official page post (Dec 19, 2025) announcing his 2025 Hubertus Wald Prize in Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →theranostictrials.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gustaveroussy.fr ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bulletins-officiels.social.gouv.fr ↗
- Chair
French Genitourinary Tumour Group (GETUG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗ - Head
genitourinary oncology group, Institut Gustave Roussy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gustaveroussy.fr ↗
Awards & honors
honors on the public record- Hubertus Wald Prize in Oncology 2025 (University Hospital Hamburg-Eppendorf)
for research advancing prostate/testicular tumor therapies
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗ - ESMO Award 2022
for pioneering research in genitourinary (prostate, ureter, bladder, testis) cancers
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →drozdogan.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗
- Institut Gustave Roussy
Villejuif, Medical Oncologist; directed the Department of Cancer Medicine 2005-2018; head of genitourinary oncology group
2018verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gustaveroussy.fr ↗ - Founder
PEACE consortium (Prostate Cancer Consortium in Europe), 2014, coordinating ~10 Phase 3 trials including PEACE-1 and PEACE-2
2014verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centreoscarlambret.fr ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gustaveroussy.fr ↗
- Medical Advisory Board member
Mabqi (biotech)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mabqi.com ↗ - Editorial role at European Journal of Cancer
described inconsistently across sources as "Deputy Editor-in-Chief" (Centre Oscar Lambret), "Associate Editor" (Mabqi, Gustave Roussy bio) …
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →centreoscarlambret.fr ↗
Media & interviews
press, podcasts and appearances- UroToday video lecture series
multiple interviews including PEACE-2 trial results (ASCO GU 2026) and treatment-decision discussions in castration-resistant prostate cancer
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- The ASCO Post video interview
"Karim Fizazi on Prostate Cancer Abiraterone Acetate, Prednisone, and Radiotherapy in Metastatic Disease"
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Prostate Cancer Update podcast (Research To Practice)
"Interview with Karim Fizazi, MD, PhD", March 31, 2020, cross-listed on Apple Podcasts, player.fm, Audible, TuneIn
2020provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dailymotion.com ↗
- ASCO Daily News Podcast
"Dr. Karim Fizazi on the PEACE-1 Trial & Improving Outcomes in mCSPC"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dailynews.ascopubs.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Éric Dansin
Centre Oscar Lambret
Audrey Mailliez
Centre Oscar Lambret
Laurence Vanlemmens
Centre Oscar Lambret
M O Vilain
Centre Oscar Lambret
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)